Zydus Lifesciences reported a 26.6% decline in consolidated net profit for the September quarter, reaching 925.5 crore rupees, which was attributed to increased expenses. In the corresponding period last fiscal year, the company reported a net profit of 1,260.9 crore rupees, according to regulatory filings submitted to the stock exchanges.
For the reporting quarter, operating revenue increased to 7,909.6 crore rupees compared to 6,123.2 crore rupees a year earlier. However, Zydus's total expenses rose significantly, amounting to 6,806.6 crore rupees in the current quarter, whereas they were 4,509 crore rupees in the same period last year.
During this quarter, the pharmaceutical business accounted for 83% of the company's sales. Notably, the prescription drug division in India generated revenue of 1,884.4 crore rupees, showing an 18% year-on-year growth. The North American prescription drug business generated revenue of 3,314.5 crore rupees, demonstrating a 21% growth, resulting from sustained expansion of the core business volume and the ongoing scaling of the American specialty segment.
Zydus Lifesciences Managing Director, Sharvil Patel, noted that the second-quarter results reflect a strong overall momentum led by branded segments in India, international markets, and the wellness sector. He emphasized that the share of branded product sales in the US grew to 16%, indicating the company's systematic shift towards a more differentiated portfolio focused on specialized products. Patel added that the company expects approval and launch of Saroglitazar in the US, which is the first domestic discovery of a new chemical entity (NCE) and marks a significant milestone in its development.
Furthermore, for the period from April to September of the 2027 fiscal year, the pharmaceutical company's net profit decreased by 30.86% to 1,885.9 crore rupees compared to 2,727.7 crore rupees a year earlier. At the time of publication, Zydus Lifesciences shares were trading at BSE at Rs 1,197.50 per share, down by 3.35%.



